The ARMC8 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human ARMC8 gene in the SK-HEP-1 hepatocellular carcinoma cell line. This loss-of-function model is generated by CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous pool of edited cells that collectively ablate ARMC8 expression. The polyclonal format preserves the genetic diversity inherent to the editing process, providing a robust experimental system for studying gene function without the clonal artifacts often associated with single-cell-derived lines. This product is intended for advanced biomedical research, enabling dissection of ARMC8-dependent pathways in a clinically relevant liver cancer background.
The host cell line SK-HEP-1 is an endothelial-like hepatocellular carcinoma model originally derived from the ascites of a patient with liver adenocarcinoma. These cells exhibit a unique hybrid phenotype, combining epithelial and endothelial characteristics, which makes them particularly valuable for investigating liver tumorigenesis, cancer cell plasticity, and metastatic progression. SK-HEP-1 cells are widely used in functional genomics and drug discovery studies focused on hepatocellular carcinoma, offering a versatile platform for assessing tumor cell behavior, including proliferation, migration, and invasion. The knockout of ARMC8 in this context provides a direct approach to study how perturbed ubiquitin-mediated proteolysis influences hepatocellular carcinoma pathophysiology.
ARMC8 functions as a core scaffold protein within the CTLH (C-terminal to LisH) E3 ubiquitin ligase complex, where it facilitates the assembly of subunits such as MAEA, RMND5A, GID4, and WDR26. Through this complex, ARMC8 promotes ubiquitination and subsequent proteasomal degradation of key substrates, including HMGCS2 and HBP1, thereby regulating mTORC1 signaling and cell cycle progression. ARMC8 activity is influenced by upstream nutrient-sensing pathways, including mTORC1 and AMPK, and its loss leads to stabilization of downstream targets like NRF2 and c-MYC, triggering dysregulation of the ubiquitin-proteasome system, mTOR signaling, and Wnt/??-catenin pathways. Additionally, ARMC8-mediated degradation is critical for controlling cell migration and maintaining proper cell cycle checkpoints.
In the hepatocellular carcinoma context, ARMC8 knockout disrupts CTLH complex integrity, causing accumulation of tumor-suppressive and oncogenic substrates that rewire signaling networks central to liver cancer biology. This model enables researchers to dissect the dual roles of ubiquitin-dependent proteolysis in tumor suppression and oncogenesis, as the SK-HEP-1 background recapitulates key aspects of hepatic malignancy. The polyclonal knockout population is particularly suited for studying heterogeneous cellular responses, as it mirrors the genetic variability found in tumors. By exploring how loss of ARMC8 alters substrate turnover and pathway outputs, scientists can identify vulnerabilities in hepatocellular carcinoma that may be exploited for therapeutic intervention, especially in targeting the ubiquitin-proteasome system or mTOR axis.
This ARMC8 knockout model supports a wide array of research applications, including functional genomics of liver cancer, characterization of CTLH complex biology, and mechanistic studies of ubiquitin-mediated regulation in cell proliferation and metastasis. Typical assays include Western blotting for CTLH components and substrates like HMGCS2 and HBP1, RT-qPCR for downstream targets, proliferation and migration assays, colony formation, apoptosis assays, and co-immunoprecipitation to assess complex assembly. The model is also amenable to ubiquitination assays, xenograft tumor studies, and drug sensitivity screening, making it a powerful tool for investigating targeted therapies against the ubiquitin-proteasome system in hepatocellular carcinoma. For further details, please contact Ascent Research.
